$KBLM News
Last published 6y ago
- 6y agoKBLMKBL Merger Corp. IV Announces Completion of Acquisition of 180 Life Sciences Corp. and Trading Under the ticker ATNF Starting November 9, 2020GlobeNewswireNEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC), today announced the successful completion of its...
- 6y agoKBLMKBL Merger Corp. IV Announces Approval of Business Combination with 180 Life Sciences at the Special Meeting of Shareholders Held on November 5, 2020GlobeNewswireNEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire 180...
- 6y agoKBLMKBL Merger Corp. IV Announces Change of Special Meeting of Shareholders Date to November 5, 2020GlobeNewswireNEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire 180...
- 6y agoKBLMInnovative Companies with Blockbuster Potential Catch SPAC AttentionGlobeNewswireNEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- NetworkNewsAudio – 180 Life Sciences Corp., a clinical-stage biotechnology company that has entered into a definitive merger agreement with KBL Merger...
- 6y agoKBLMKBLMRKBLMWALXN+3In Pursuit of the Elusive Drug -- the Billion-Dollar BlockbusterPR NewswireEnormous amounts of money exchange hands in the big pharma space as companies merge and are acquired — all in search of the next blockbuster drug....
- 6y agoKBLMUPDATE -- The Quest for Blockbuster Drugs ContinuesGlobeNewswireNEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire — 180 Life Sciences Corp., a clinical-stage biotechnology company that has entered into a definitive merger agreement with KBL Merger...
- 6y agoKBLMKBLMRKBLMWJNJ+3Banking on the Next Blockbuster DrugPR NewswirePharmaceutical companies invest enormous amounts of time and money on the research and development of new drugs, typically years in the making and...
- 6y agoKBLMLLYMRKRATA+1SPACs Surge as Biotech BoomsPR NewswireAs the world has focused on the search for COVID vaccines and therapeutics, biotech IPOs have quietly gone bonkers. As a matter of fact, 2020 is on...
- 6y agoKBLMPromising Biotechs Choosing SPAC for Speed, Capital, VisibilityGlobeNewswireNEW YORK, Oct. 14, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- 180 Life Sciences Corp. today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ brands in...
- 6y agoKBLMIMTXIMVTAHCO+1Blockbuster Year and Bright Horizons for SPACsPR NewswireThe year 2020 has already seen 127 SPAC IPOs, which have collectively raised over $48.5 billion in proceeds — more than the past ten years combined....
- 6y agoKBLMKBL Merger Corp. IV Announces Special Meeting of Shareholders to be Held October 26, 2020 upon the SEC Declaring the S-4 Registration Statement EffectiveGlobeNewswireNEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced the acquisition of 180 Life...
- 6y agoKBLMUPDATE: 180 Life Sciences Corp. Expands Intellectual Property PortfolioGlobeNewswireNEW YORK, Oct. 06, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced the signing of a definitive...
- 6y agoKBLM180 Life Sciences Corp. Expands Intellectual Property PortfolioGlobeNewswireNEW YORK, Oct. 06, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced the signing of a definitive...
- 6y agoKBLM180 Life Science Corp. Announces New Board of Directors AppointmentsGlobeNewswireNEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced the signing of a definitive...
- 6y agoKBLMDevelopment of Next-Generation Drugs to Inhibit Ravages of Chronic InflammationGlobeNewswireNEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- NetworkNewsAudio – 180 Life Sciences Corp. (NASDAQ: KBLM) announces the availability of a broadcast titled, “Solving One of the Largest Drivers of...
- 6y agoKBLMADAPAIMTIMVT+3Life-Saving Advancements, Treatments Delivered by Companies Invested in InnovationPR NewswireInnovation and breakthroughs in the biotech industry are essential to identifying and providing life-saving treatments. Companies that invest...
- 6y agoKBLMGroundbreaking Studies Offer Hope for Unmet Medical Needs in Inflammatory DiseaseGlobeNewswireNEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- via NetworkNewsWire -- 180 Life Sciences Corp. (NASDAQ: KBLM) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of...
- 6y agoKBLMAMGNABBVJNJSolving One of the Largest Drivers of Disease: InflammationPR NewswireInflammation typically occurs in the body as a natural response to threats such as infection or injury, but chronic inflammation can cause severe...
- 6y agoKBLMKBL Merger Corp. IV SPAC Successfully Completes Bridge FinancingPR NewswireKBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition corporation (SPAC) that previously announced the signing of a...
- 7y agoKBLMKBL Merger Corp. IV SPAC Signs Definitive Business Combination Agreement to Acquire CannBioRx Life Sciences Corp.PR NewswireKBL Merger Corp. IV (NASDAQ: KBLM) ("KBLM"), a Special Purpose Acquisition Company (SPAC), announced today that it has executed a definitive business ...